Claims for Patent: 9,694,015
✉ Email this page to a colleague
Summary for Patent: 9,694,015
Title: | Methods for the treatment of locally advanced breast cancer |
Abstract: | Provided herein are methods of treating, preventing and/or managing locally advanced breast cancer, including inflammatory breast cancer, which comprise administering to a patient one or more immunomodulatory compounds or enantiomers or mixtures of enantiomers thereof, or pharmaceutically acceptable salts, solvates, hydrates, co-crystals, clathrates, or polymorphs thereof. |
Inventor(s): | Gandhi; Anita (Bernardsville, NJ), Dimartino; Jorge (Belmont, NJ), Chopra; Rajesh (Summit, NJ) |
Assignee: | Celgene Corporation (Summit, NJ) |
Application Number: | 14/426,114 |
Patent Claims: | 1. A method of treating or managing locally advanced breast cancer comprising administering to a patient in need of such treatment or management a therapeutically effective
amount of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or mixture of enantiomers thereof; or a pharmaceutically acceptable salt, co-crystal, or clathrate thereof.
2. The method of claim 1, wherein the locally advanced breast cancer is inflammatory breast cancer. 3. The method of claim 1, wherein the cancer is relapsed or refractory. 4. The method of claim 1, wherein the cancer is drug-resistant. 5. The method of claim 1, wherein the compound is 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or a salt thereof. 6. The method of claim 1, further comprising the administration of a therapeutically effective amount of one or more additional active agents. 7. The method of claim 6, wherein the additional active agent is selected from the group consisting of paclitaxel, docetaxel, protein-bound paclitaxel, 5-azacytidine, capecitabine, gemcitabine, romidepsin, vorinostat, panobinostat, valproic acid, belinostat, etinostat, trastuzumab, trastuzumab emtansine, lapatinib, bevacizumab, pertuzumab, doxorubicin, daunorubicin, mitoxantrone, amsacrine, aurintricarboxylic acid, irinotecan, topotecan, camtothecin, lamellarin D, etoposide, teniposide, tamoxifen, cisplatin, carboplatin, oxaliplatin, vinblastine, vincristine, vindesine, vinorelbine, navitoclax, a Bcl-2 inhibitor, and PI3K/AKT/mTOR pathway inhibitor. 8. The method of claim 1, wherein the compound, or a pharmaceutically acceptable salt thereof, is administered in an amount of from about 0.5 to about 50 mg per day. 9. The method of claim 8, wherein the compound, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 5 mg per day. 10. The method of claim 8, wherein the compound, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5, 1, 2, 4, 5, 10, 15, 20, 25 or 50 mg per day. 11. The method of claim 8, wherein the compound, or a pharmaceutically acceptable salt thereof, is orally administered. 12. The method of claim 8, wherein the compound, or a pharmaceutically acceptable salt thereof, is administered in a capsule or tablet. 13. The method of claim 8, wherein the compound is administered in 10 mg or 25 mg of a capsule. 14. The method of claim 1, wherein the compound is administered for 21 days followed by seven days rest in a 28 day cycle. 15. A method for treating or managing locally advanced breast cancer, comprising: (i) identifying a patient having locally advanced breast cancer sensitive to treatment with 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or mixture of enantiomers thereof; or a pharmaceutically acceptable salt co-crystal, or clathrate thereof; and (ii) administering to the patient a therapeutically effective amount the compound selected in step (i). 16. The method of claim 15, wherein the locally advanced breast cancer is inflammatory breast cancer. 17. The method of claim 15, wherein identifying a patient having locally advanced breast cancer sensitive to treatment comprises detecting the level of expression of CRBN, Aiolos (IKZF3) or Ikaros (IKZF1) expression within the cancer. |
Details for Patent 9,694,015
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2032-09-10 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2032-09-10 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2032-09-10 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.